BioProcess International Announces Winners of the 2014 BioProcess International Awards
New York, NY (PRWEB) October 23, 2014 -- BioProcess International (BPI), a business-to-business publication, today announced the winners for the 2014 BioProcess International Awards. The awards celebrate the outstanding achievements, collaborations, business strategies, social corporate responsibility and technology applications that will allow the industry to deliver better, more effective treatments to a global patient base.
Winners and finalists were honored and recognized by their peers during a very entertaining and exciting awards dinner and ceremony yesterday evening, 22 October at the Hynes Convention Center in Boston.
Winners and Finalists for the 2014 BioProcess International Awards are:
Excellence in Leadership
• (Winner) Dr. Robert Preti, Founder, President, and Chief Scientific Officer, Progenitor Cell Therapy (PCT)
• (Finalist) Lynn Bottone, Site Leader, Sanford Site, Pfizer
• (Finalist) Olivier Loeillot, General Manager, Enterprise Solutions, GE Healthcare Life Sciences
Emerging Company
• (Winner) ToleRaM Nanotech, LLC.
• (Finalist) BioCision
• (Finalist) Horizon Discovery
Corporate Citizenship
• (Winner) Bayer HealthCare
• (Finalist) Biogen Idec
• (Finalist) Sigma-Aldrich
Excellence in Facility Design or Retrofit
• (Winner) Gallus BioPharmaceuticals/GE Healthcare Life Sciences
• (Finalist) Vetter
• (Finalist) FUJIFILM Diosynth Biotechnologies
Best Collaboration
• (Winner) TAP Biosystems/Merck & Co., Inc.
• (Finalist) Invetech Inc./Janssen Research & Development, LLC
• (Finalist) Promosome/GE Healthcare Life Sciences
Upstream: Best Technology Applications
• (Winner) ambr250 — TAP Biosystems/Merck & Co., Inc.
• (Finalist) XDR-50 MO Fermentor System — GE Healthcare Life Sciences
• (Finalist) STX® Scalable Transfection System — MaxCyte
Downstream: Best Technology Applications
• (Winner) Natrix HD Membranes — Natrix Separations, Inc. /Gallus BioPharmaceuticals
• (Finalist) BioT Temperature Stability Systems — BioCision
• (Finalist) Allegro Single-Use Filling Needles — Pall Life Sciences/Disposable-Lab SAS
Analytical: Best Technology Applications
• (Winner) MicroScale Thermophoresis (MST) — NanoTemper Technologies GmbH
• (Finalist) ImageStreamX®(ISX) — Enzo Life Sciences/Amnis (part of EMD Millipore)
• (Finalist) SGS M-Scan Services — SGS Life Sciences
From Some of the Award Winners:
“It is a fantastic honor to be nominated for the BioProcess International 2014 Award, along with TAP Biosystems, for both Best Collaboration and Best Technology Application-Upstream for the development of the Ambr250 automated bioreactor system. The collaboration and resulting Ambr250 technology was intended to have true value to end users through the improvement of productivity, accuracy, consistency, and the work life balance of the scientist. Being nominated as a finalist in these categories shows the value the technology brings to these areas,” said David Pollard, Executive Director, Merck & Co., Inc.
“We spend a lot of time trying to understand the requirements of the end-users and the context into which our systems are placed. Being a BioProcess International 2014 Awards finalist with the excellent team from Merck is an acknowledgement that such time and effort is really worthwhile,” said Richard Wales, Director Business Development, TAP Biosystems, Part of the Sartorius Stedim Biotech Group.
“ToleRaM Nanotech is delighted with being recognized as a finalist for the BioProcess International 2014 "Emerging Company" award. We are dedicated to the efficient delivery of targeted nanotherapeutics by merging bioengineering with medicine, and are truly honored by this recognition,” said Satish N. Nadig, M.D., Ph.D. Title: Chief Medical Officer (CMO) ToleRaM Nanotech; Assistant Professor of Surgery, Microbiology & Immunology - Medical University of South Carolina.
For more quotes from our finalists and winners visit: http://www.bioprocessintl.com/awardsfinalists-2014
About Our Sponsors
Program Sponsors:
GE Healthcare Life Sciences provides tools and technologies, solutions, and services that enable the biopharmaceutical industry to develop and manufacture biotherapeutic medicines and vaccines cost-effectively. Our products and platform solutions are designed to meet the key challenges posed at every stage in the biomanufacturing process, delivering the desired product at the required purity and safety — all with fast development and integrated solutions in mind. Across the bioprocessing spectrum, our focus is on supporting the industry from idea to result.
Pall Life Sciences provides process, pilot and laboratory filtration, separation, purification, and fluid handling devices, systems, and services with single-use systems available for all unit operations from cell culture through final formulation and filling. Based on Pall’s long history of providing quality equipment for the biopharmaceutical, vaccine, and cell therapy industries, all products — whether standard or customized to match users exact process needs — are backed up with extensive documentation and experience in extractables, leachables, and particulate validation. Fully automated single-use systems allow process control and data acquisition to meet or exceed the standards expected from traditional fixed equipment. New product highlights include microcarriers, pyrogen-free vials, and a range of pharmaceutical packaging.
Sartorius Stedim Biotech is one of the world's leading providers of laboratory and process technologies and equipment. Our innovative products and high-quality services help customers implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. Sartorius Stedim Biotech introduced the first single-use bag for biopharmaceutical applications. Demand for these bioprocessing bags has rapidly increased for use in critical applications. We have developed a new polyethylene film and new bioprocessing bags to pave the way toward the single-use manufacturing facility of the future. Flexsafe meets the most stringent customer needs for safe bioprocessing.
Associate Sponsor:
Rentschler is an independent, family-owned biopharmaceutical CMO with a long-term track record, high level of flexibility, and tailored project performance. Our full-service concept covers development, production of recombinant proteins in mammalian cell lines, fill–finish and international regulatory expertise. Our state-of-the-art facilities with bioreactors up to 3,500 L total volume and our quality control ensure highest quality.
About BioProcess International
BioProcess International (BPI) is a business-to-business publication dedicated to delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals and therapeutics. Learn more at http://www.bioprocessintl.com.
Photo Caption:
S. Anne Montgomery (left) editor-in-chief and co-founder, BioProcess International magazine honors Best Facility Design/Retrofit winners Gallus Biopharmaceuticals and GE Healthcare Life Sciences. Accepting the award from Gallus Biopharmaceuticals is Mike Ultee (center), chief scientific officer. Accepting the award from GE Healthcare Life Sciences is Geoff Hodge (right), biomanufacturing services leader.
Leah Rosin, BioProcess International, http://www.bioprocessintl.com, +1 508-614-1677, [email protected]
Share this article